Protocol Page


	Study ID (Protocol Number)
	CA209-025


	STUDY LOCATIONS*
	Beth Israel Deaconess Medical Center Boston, MA 02215 Recruiting	Cancer Therapy And Research Center San Antonio, TX 78229 Recruiting
	Beth Israel Deaconess Medical Center Boston, MA 02215 Recruiting	Cedar Sinai Medical Center Los Angeles, CA 90048 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC
	STUDY OVERVIEW
	The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of BMS-936558 vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.